Bristol-Myers Squibb has received
FDA approval for its novel
schizophrenia drug, the first of its kind in several decades, sparking a positive trend in the company's
stock price. Presently, Bristol-Myers Squibb's stock is attracting
investor attention, and the company appears amongst the dividend giants with the lowest short interest in 2024. Furthermore,
Bristol Myers Squibb and
2seventy have had to abandon the Abecma trial for first-line myeloma due to enrollment challenges. As part of its cost-reduction program,
BMS is laying off 79 employees in Lawrenceville, NJ, which brings the city's cuts to 1,134. The company also presented new data demonstrating
Sotyktu's (deucravacitinib) efficacy in treating moderate-to-severe scalp psoriasis in both clinical and real-world settings. However,
BMS stock dipped slightly in the broader market, amidst reports of a discontinuation in enrolment for a multiple myeloma trial and a dip in net income for Q2 2024.
Bristol-Myers Squibb News Analytics from Wed, 17 Jan 2024 08:00:00 GMT to Sat, 28 Sep 2024 07:46:38 GMT -
Rating 7
- Innovation 6
- Information 9
- Rumor -3
